Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells
of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for …

B cell generation of autoantibodies is a crucial step in the pathogenesis of systemic lupus
erythematosus (SLE). After their differentiation in the bone marrow, B cells populate the …

Background Treatment for autoimmune diseases such as systemic lupus erythematosus
(SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term …

Anti-CD19 chimeric antigen receptor (CAR)-T cells not only target CD19-positive malignant
lymphoma cells but also normal B cells. The utility of CAR-T cell therapy has been reported …

Our objective in this review article is to present a clinical case of a patient with
antisynthetase syndrome (ASyS) and provide an overview of the pathogenesis, classification …

Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread
with cancer through the underlying mechanism of inflammation. This inflammatory milieu not …

Chimeric antigen receptor T cell (CAR-T) therapy, an innovative immune cell therapy, has
revolutionized the treatment landscape of haematological malignancies. The past 2 years …

Under compassionate use, chimeric antigen receptor (CAR) T cells have elicited durable
remissions in patients with refractory idiopathic inflammatory myopathies (IIMs). Here, we …

The administration of T cells that have been modified to carry chimeric antigen receptors
(CARs) aimed at B cells has been an effective strategy in treating B cell malignancies. This …

B-cell depletion therapy (BCDT) has been employed to treat autoimmune disease for~ 20
years. Immunoglobulin G1 (IgG1) monoclonal antibodies targeting CD20 and utilizing …